Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022
This report studies the global Therapies for Resistant and Recurrent Metastatic Cancer market, analyzes and researches the Therapies for Resistant and Recurrent Metastatic Cancer development status and forecast in United States, EU, Japan, China, India and Southeast Asia.
This report focuses on the top players in global market, like
This report focuses on the top players in global market, like
- Miraca Holdings
- Proteome Sciences
- Boreal Genomics
- Oxford Gene Technology
- Illumina
- Neogenomics Laboratories
- Biotheranostics
- Nanostring Technologies
- Genomic Health
- Thermo Fisher Scientific
- United States
- EU
- Japan
- China
- India
- Southeast Asia
- Breast Cancer
- Endocrine Cancer
- Leukemia
- Lymphoma
- Bladder
- Colorectal
- Kidney
- Ovary
- Pancreas
- Others
- Chemotherapy
- Hormone Therapy
- Biotherapy
- Radiation Therapy
- Surgery
- Others
Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022
1 INDUSTRY OVERVIEW OF THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER
1.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Overview
1.1.1 Therapies for Resistant and Recurrent Metastatic Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Therapies for Resistant and Recurrent Metastatic Cancer Market by Type
1.3.1 Breast Cancer
1.3.2 Endocrine Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Bladder
1.3.6 Colorectal
1.3.7 Kidney
1.3.8 Ovary
1.3.9 Pancreas
1.3.10 Others
1.4 Therapies for Resistant and Recurrent Metastatic Cancer Market by End Users/Application
1.4.1 Chemotherapy
1.4.2 Hormone Therapy
1.4.3 Biotherapy
1.4.4 Radiation Therapy
1.4.5 Surgery
1.4.6 Others
2 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER COMPETITION ANALYSIS BY PLAYERS
2.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 COMPANY (TOP PLAYERS) PROFILES
3.1 Miraca Holdings
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Proteome Sciences
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Boreal Genomics
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Oxford Gene Technology
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Illumina
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Neogenomics Laboratories
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Biotheranostics
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Nanostring Technologies
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 Genomic Health
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 Thermo Fisher Scientific
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.10.5 Recent Developments
4 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE BY TYPE AND APPLICATION (2012-2017)
4.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Type (2012-2017)
4.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2012-2017)
4.3 Potential Application of Therapies for Resistant and Recurrent Metastatic Cancer in Future
4.4 Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer
5 UNITED STATES THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
5.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
5.2 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
6 EU THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
6.1 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
6.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
7 JAPAN THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
7.1 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
7.2 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
8 CHINA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
8.1 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
8.2 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
9 INDIA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
9.1 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
9.2 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
10 SOUTHEAST ASIA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
10.1 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
10.2 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
11 MARKET FORECAST BY REGIONS, TYPE AND APPLICATION (2017-2022)
11.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Regions (2017-2022)
11.1.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.3 Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.4 China Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.5 India Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.6 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Type (2017-2022)
11.3 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2017-2022)
12 THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET DYNAMICS
12.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Opportunities
12.2 Therapies for Resistant and Recurrent Metastatic Cancer Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Therapies for Resistant and Recurrent Metastatic Cancer Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Therapies for Resistant and Recurrent Metastatic Cancer Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 MARKET EFFECT FACTORS ANALYSIS
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 RESEARCH FINDING/CONCLUSION
15 APPENDIX
Methodology
Analyst Introduction
Data Source
The report requires updating with new data and is sent in 2-3 business days after order is placed.
1 INDUSTRY OVERVIEW OF THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER
1.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Overview
1.1.1 Therapies for Resistant and Recurrent Metastatic Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Therapies for Resistant and Recurrent Metastatic Cancer Market by Type
1.3.1 Breast Cancer
1.3.2 Endocrine Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Bladder
1.3.6 Colorectal
1.3.7 Kidney
1.3.8 Ovary
1.3.9 Pancreas
1.3.10 Others
1.4 Therapies for Resistant and Recurrent Metastatic Cancer Market by End Users/Application
1.4.1 Chemotherapy
1.4.2 Hormone Therapy
1.4.3 Biotherapy
1.4.4 Radiation Therapy
1.4.5 Surgery
1.4.6 Others
2 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER COMPETITION ANALYSIS BY PLAYERS
2.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 COMPANY (TOP PLAYERS) PROFILES
3.1 Miraca Holdings
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Proteome Sciences
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Boreal Genomics
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Oxford Gene Technology
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Illumina
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Neogenomics Laboratories
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Biotheranostics
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Nanostring Technologies
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 Genomic Health
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.9.5 Recent Developments
3.10 Thermo Fisher Scientific
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
3.10.5 Recent Developments
4 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE BY TYPE AND APPLICATION (2012-2017)
4.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Type (2012-2017)
4.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2012-2017)
4.3 Potential Application of Therapies for Resistant and Recurrent Metastatic Cancer in Future
4.4 Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer
5 UNITED STATES THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
5.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
5.2 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
6 EU THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
6.1 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
6.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
7 JAPAN THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
7.1 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
7.2 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
8 CHINA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
8.1 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
8.2 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
9 INDIA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
9.1 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
9.2 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
10 SOUTHEAST ASIA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK
10.1 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
10.2 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)
11 MARKET FORECAST BY REGIONS, TYPE AND APPLICATION (2017-2022)
11.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Regions (2017-2022)
11.1.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.3 Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.4 China Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.5 India Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.1.6 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
11.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Type (2017-2022)
11.3 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2017-2022)
12 THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET DYNAMICS
12.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Opportunities
12.2 Therapies for Resistant and Recurrent Metastatic Cancer Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Therapies for Resistant and Recurrent Metastatic Cancer Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Therapies for Resistant and Recurrent Metastatic Cancer Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 MARKET EFFECT FACTORS ANALYSIS
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 RESEARCH FINDING/CONCLUSION
15 APPENDIX
Methodology
Analyst Introduction
Data Source
The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES
Figure Therapies for Resistant and Recurrent Metastatic Cancer Product Scope
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) (2012-2017)
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Regions in 2016
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Type in 2016
Figure Breast Cancer Market Size (Million USD) and Growth Rate (2012-2017)
Figure Endocrine Cancer Market Size (Million USD) and Growth Rate (2012-2017)
Figure Leukemia Market Size (Million USD) and Growth Rate (2012-2017)
Figure Lymphoma Market Size (Million USD) and Growth Rate (2012-2017)
Figure Bladder Market Size (Million USD) and Growth Rate (2012-2017)
Figure Colorectal Market Size (Million USD) and Growth Rate (2012-2017)
Figure Kidney Market Size (Million USD) and Growth Rate (2012-2017)
Figure Ovary Market Size (Million USD) and Growth Rate (2012-2017)
Figure Pancreas Market Size (Million USD) and Growth Rate (2012-2017)
Figure Others Market Size (Million USD) and Growth Rate (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Application in 2016
Table Key Downstream Customer in Chemotherapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Chemotherapy (2012-2017)
Table Key Downstream Customer in Hormone Therapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Hormone Therapy (2012-2017)
Table Key Downstream Customer in Biotherapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Biotherapy (2012-2017)
Table Key Downstream Customer in Radiation Therapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Radiation Therapy (2012-2017)
Table Key Downstream Customer in Surgery
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Surgery (2012-2017)
Table Key Downstream Customer in Others
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Others (2012-2017)
Table Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2016 and 2017)
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Table Miraca Holdings Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Miraca Holdings (2012-2017)
Figure Miraca Holdings Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Proteome Sciences Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Proteome Sciences (2012-2017)
Figure Proteome Sciences Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Boreal Genomics Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Boreal Genomics (2012-2017)
Figure Boreal Genomics Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Oxford Gene Technology Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Oxford Gene Technology (2012-2017)
Figure Oxford Gene Technology Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Illumina Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Illumina (2012-2017)
Figure Illumina Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Neogenomics Laboratories Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Neogenomics Laboratories (2012-2017)
Figure Neogenomics Laboratories Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Biotheranostics Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Biotheranostics (2012-2017)
Figure Biotheranostics Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Nanostring Technologies Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Nanostring Technologies (2012-2017)
Figure Nanostring Technologies Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Genomic Health Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Genomic Health (2012-2017)
Figure Genomic Health Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Thermo Fisher Scientific Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Thermo Fisher Scientific (2012-2017)
Figure Thermo Fisher Scientific Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Type (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2012
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2013
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2014
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2015
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2016
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2017
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2012
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2013
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2014
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2015
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2016
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2017
Table Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Regions (2017-2022)
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Regions (2017-2022)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Regions in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Regions in 2022
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Type (2017-2022)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2022
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application (2017-2022)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2022
Figure Therapies for Resistant and Recurrent Metastatic Cancer Product Scope
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) (2012-2017)
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Regions in 2016
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Type in 2016
Figure Breast Cancer Market Size (Million USD) and Growth Rate (2012-2017)
Figure Endocrine Cancer Market Size (Million USD) and Growth Rate (2012-2017)
Figure Leukemia Market Size (Million USD) and Growth Rate (2012-2017)
Figure Lymphoma Market Size (Million USD) and Growth Rate (2012-2017)
Figure Bladder Market Size (Million USD) and Growth Rate (2012-2017)
Figure Colorectal Market Size (Million USD) and Growth Rate (2012-2017)
Figure Kidney Market Size (Million USD) and Growth Rate (2012-2017)
Figure Ovary Market Size (Million USD) and Growth Rate (2012-2017)
Figure Pancreas Market Size (Million USD) and Growth Rate (2012-2017)
Figure Others Market Size (Million USD) and Growth Rate (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Application in 2016
Table Key Downstream Customer in Chemotherapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Chemotherapy (2012-2017)
Table Key Downstream Customer in Hormone Therapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Hormone Therapy (2012-2017)
Table Key Downstream Customer in Biotherapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Biotherapy (2012-2017)
Table Key Downstream Customer in Radiation Therapy
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Radiation Therapy (2012-2017)
Table Key Downstream Customer in Surgery
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Surgery (2012-2017)
Table Key Downstream Customer in Others
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Others (2012-2017)
Table Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2016 and 2017)
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Table Miraca Holdings Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Miraca Holdings (2012-2017)
Figure Miraca Holdings Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Proteome Sciences Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Proteome Sciences (2012-2017)
Figure Proteome Sciences Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Boreal Genomics Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Boreal Genomics (2012-2017)
Figure Boreal Genomics Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Oxford Gene Technology Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Oxford Gene Technology (2012-2017)
Figure Oxford Gene Technology Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Illumina Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Illumina (2012-2017)
Figure Illumina Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Neogenomics Laboratories Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Neogenomics Laboratories (2012-2017)
Figure Neogenomics Laboratories Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Biotheranostics Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Biotheranostics (2012-2017)
Figure Biotheranostics Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Nanostring Technologies Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Nanostring Technologies (2012-2017)
Figure Nanostring Technologies Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Genomic Health Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Genomic Health (2012-2017)
Figure Genomic Health Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Thermo Fisher Scientific Basic Information List
Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Thermo Fisher Scientific (2012-2017)
Figure Thermo Fisher Scientific Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Type (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2012
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2013
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2014
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2015
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2016
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2017
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application (2012-2017)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2012
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2013
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2014
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2015
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2016
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2017
Table Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Regions (2017-2022)
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Regions (2017-2022)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Regions in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Regions in 2022
Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure China Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure India Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Type (2017-2022)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2022
Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application (2017-2022)
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2017
Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2022
